FDA Lifts Clinical Hold On Arbutus's Oral Hepatitis B Drug AB-101; Company Weighs Next Steps
The company says it may now pursue more U.S. clinical development of AB-101 and is evaluating next steps for the oral PD-L1 inhibitor.
Arbutus Biopharma said Thursday that the FDA has removed the clinical hold on the investigational application for AB-101, its oral PD-L1 inhibitor for chronic hepatitis B. The company disclosed the news in an 8-K filing that attaches its press release.
What the company said
Arbutus said the FDA notified it that the hold on the Investigational New Drug application, the filing that lets a drug be tested in people, has been removed. The company may now engage in additional clinical development of AB-101 in the United States.
The release says only that Arbutus "is evaluating next steps for the continued development of AB-101." It gives no trial plans or timeline.
AB-101 has the potential to activate a patient's hepatitis B virus-specific immune response by inhibiting PD-L1, according to the company.
The data behind the drug
AB-101 has completed an early-stage trial, a Phase 1a/1b study, of single and multiple ascending oral doses in healthy subjects and patients with chronic hepatitis B. Arbutus said the drug was generally well tolerated.
At the 30mg dose, the company reported evidence of high receptor occupancy in seven chronic hepatitis B patients. It also reported a decline in hepatitis B surface antigen in two patients.
The company describes AB-101 as designed to allow controlled checkpoint blockade while minimizing the systemic safety issues typically seen with checkpoint antibody therapies.
The market it targets
The World Health Organization estimates that over 250 million people worldwide have chronic hepatitis B infection, the release says. It adds that other estimates put the U.S. figure at about 2 million, and that about 1.1 million people die each year from complications of the infection.
Arbutus shares closed at $4.18 on Wednesday, before the news was public. Arbutus also lists imdusiran (AB-729) as a second hepatitis B program.
The next marker is whatever Arbutus decides after its review of next steps for AB-101, since the release names no trial or date.
Sources
- 8-K Filing — Arbutus Biopharma Corp (ABUS) — SEC EDGAR
- Exhibit exh_991.htm — Arbutus Biopharma Corp 8-K exhibit — SEC EDGAR
- Arbutus Biopharma Says FDA Lifts Clinical Hol... — benzinga.com
- Arbutus Announces FDA Clinical Hold is Lifted on IND — globenewswire.com